Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper
Copyright © 2023 Massachusetts Medical Society..
BACKGROUND: More than half of patients with polymyalgia rheumatica have a relapse during tapering of glucocorticoid therapy. Previous studies have suggested that interleukin-6 blockade may be clinically useful in the treatment of polymyalgia rheumatica. Sarilumab, a human monoclonal antibody, binds interleukin-6 receptor α and efficiently blocks the interleukin-6 pathway.
METHODS: In this phase 3 trial, we randomly assigned patients in a 1:1 ratio to receive 52 weeks of a twice-monthly subcutaneous injection of either sarilumab (at a dose of 200 mg) plus a 14-week prednisone taper or placebo plus a 52-week prednisone taper. The primary outcome at 52 weeks was sustained remission, which was defined as the resolution of signs and symptoms of polymyalgia rheumatica by week 12 and sustained normalization of the C-reactive protein level, absence of disease flare, and adherence to the prednisone taper from weeks 12 through 52.
RESULTS: A total of 118 patients underwent randomization (60 to receive sarilumab and 58 to receive placebo). At week 52, sustained remission occurred in 28% (17 of 60 patients) in the sarilumab group and in 10% (6 of 58 patients) in the placebo group (difference, 18 percentage points; 95% confidence interval, 4 to 32; P = 0.02). The median cumulative glucocorticoid dose at 52 weeks was significantly lower in the sarilumab group than in the placebo group (777 mg vs. 2044 mg; P<0.001). The most common adverse events with sarilumab as compared with placebo were neutropenia (15% vs. 0%), arthralgia (15% vs. 5%), and diarrhea (12% vs. 2%). More treatment-related discontinuations were observed in the sarilumab group than in the placebo group (12% vs. 7%).
CONCLUSIONS: Sarilumab showed significant efficacy in achieving sustained remission and reducing the cumulative glucocorticoid dose in patients with a relapse of polymyalgia rheumatica during glucocorticoid tapering. (Funded by Sanofi and Regeneron Pharmaceuticals; SAPHYR ClinicalTrials.gov number, NCT03600818.).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:389 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 389(2023), 14 vom: 05. Okt., Seite 1263-1272 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Spiera, Robert F [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.10.2023 Date Revised 06.10.2023 published: Print ClinicalTrials.gov: NCT03600818 Citation Status MEDLINE |
|---|
| doi: |
10.1056/NEJMoa2303452 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362863687 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362863687 | ||
| 003 | DE-627 | ||
| 005 | 20231226092129.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa2303452 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1209.xml |
| 035 | |a (DE-627)NLM362863687 | ||
| 035 | |a (NLM)37792612 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Spiera, Robert F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.10.2023 | ||
| 500 | |a Date Revised 06.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT03600818 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Massachusetts Medical Society. | ||
| 520 | |a BACKGROUND: More than half of patients with polymyalgia rheumatica have a relapse during tapering of glucocorticoid therapy. Previous studies have suggested that interleukin-6 blockade may be clinically useful in the treatment of polymyalgia rheumatica. Sarilumab, a human monoclonal antibody, binds interleukin-6 receptor α and efficiently blocks the interleukin-6 pathway | ||
| 520 | |a METHODS: In this phase 3 trial, we randomly assigned patients in a 1:1 ratio to receive 52 weeks of a twice-monthly subcutaneous injection of either sarilumab (at a dose of 200 mg) plus a 14-week prednisone taper or placebo plus a 52-week prednisone taper. The primary outcome at 52 weeks was sustained remission, which was defined as the resolution of signs and symptoms of polymyalgia rheumatica by week 12 and sustained normalization of the C-reactive protein level, absence of disease flare, and adherence to the prednisone taper from weeks 12 through 52 | ||
| 520 | |a RESULTS: A total of 118 patients underwent randomization (60 to receive sarilumab and 58 to receive placebo). At week 52, sustained remission occurred in 28% (17 of 60 patients) in the sarilumab group and in 10% (6 of 58 patients) in the placebo group (difference, 18 percentage points; 95% confidence interval, 4 to 32; P = 0.02). The median cumulative glucocorticoid dose at 52 weeks was significantly lower in the sarilumab group than in the placebo group (777 mg vs. 2044 mg; P<0.001). The most common adverse events with sarilumab as compared with placebo were neutropenia (15% vs. 0%), arthralgia (15% vs. 5%), and diarrhea (12% vs. 2%). More treatment-related discontinuations were observed in the sarilumab group than in the placebo group (12% vs. 7%) | ||
| 520 | |a CONCLUSIONS: Sarilumab showed significant efficacy in achieving sustained remission and reducing the cumulative glucocorticoid dose in patients with a relapse of polymyalgia rheumatica during glucocorticoid tapering. (Funded by Sanofi and Regeneron Pharmaceuticals; SAPHYR ClinicalTrials.gov number, NCT03600818.) | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Prednisone |2 NLM | |
| 650 | 7 | |a VB0R961HZT |2 NLM | |
| 650 | 7 | |a sarilumab |2 NLM | |
| 650 | 7 | |a NU90V55F8I |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 700 | 1 | |a Unizony, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Warrington, Kenneth J |e verfasserin |4 aut | |
| 700 | 1 | |a Sloane, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Giannelou, Angeliki |e verfasserin |4 aut | |
| 700 | 1 | |a Nivens, Michael C |e verfasserin |4 aut | |
| 700 | 1 | |a Akinlade, Bolanle |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Wanling |e verfasserin |4 aut | |
| 700 | 1 | |a Bhore, Rafia |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Buttgereit, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Devauchelle-Pensec, Valerie |e verfasserin |4 aut | |
| 700 | 1 | |a Rubbert-Roth, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Yancopoulos, George D |e verfasserin |4 aut | |
| 700 | 1 | |a Marrache, Frederic |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Naimish |e verfasserin |4 aut | |
| 700 | 1 | |a Dasgupta, Bhaskar |e verfasserin |4 aut | |
| 700 | 0 | |a SAPHYR Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Caubet, Mariana |e investigator |4 oth | |
| 700 | 1 | |a Lizarraga, Ana |e investigator |4 oth | |
| 700 | 1 | |a Santiago, Maria Lida |e investigator |4 oth | |
| 700 | 1 | |a Tate, Guillermo |e investigator |4 oth | |
| 700 | 1 | |a Tate, Patricio |e investigator |4 oth | |
| 700 | 1 | |a Scaglioni, Valeria |e investigator |4 oth | |
| 700 | 1 | |a Brom, Martin |e investigator |4 oth | |
| 700 | 1 | |a Sabelli, Mirtha |e investigator |4 oth | |
| 700 | 1 | |a Zacariaz, Johana Belen |e investigator |4 oth | |
| 700 | 1 | |a Berman, Horacio |e investigator |4 oth | |
| 700 | 1 | |a Barbaglia, Federico Gerardo |e investigator |4 oth | |
| 700 | 1 | |a Cardoza, Maria Gabriela |e investigator |4 oth | |
| 700 | 1 | |a Huerta, Elena |e investigator |4 oth | |
| 700 | 1 | |a Ruiz, Natalia |e investigator |4 oth | |
| 700 | 1 | |a Spindler, Walter Javier |e investigator |4 oth | |
| 700 | 1 | |a Banos, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Sureda, Evelin |e investigator |4 oth | |
| 700 | 1 | |a Dalpiaz, Marina Soledad |e investigator |4 oth | |
| 700 | 1 | |a Di Lorenzo, Laura |e investigator |4 oth | |
| 700 | 1 | |a Perez Rosa, Adriana |e investigator |4 oth | |
| 700 | 1 | |a Serrano Eliana, Rebeca |e investigator |4 oth | |
| 700 | 1 | |a Bird, Paul |e investigator |4 oth | |
| 700 | 1 | |a Joshua, Fredrick |e investigator |4 oth | |
| 700 | 1 | |a Kumar, Shweta |e investigator |4 oth | |
| 700 | 1 | |a Tay, Tien |e investigator |4 oth | |
| 700 | 1 | |a De Wet, Peter |e investigator |4 oth | |
| 700 | 1 | |a Hutton, Ingrid |e investigator |4 oth | |
| 700 | 1 | |a Johnson, Frances |e investigator |4 oth | |
| 700 | 1 | |a Nash, Peter |e investigator |4 oth | |
| 700 | 1 | |a Nicholls, Dave |e investigator |4 oth | |
| 700 | 1 | |a Thackwray, Susan |e investigator |4 oth | |
| 700 | 1 | |a Anderson, Ross |e investigator |4 oth | |
| 700 | 1 | |a Cheung, King |e investigator |4 oth | |
| 700 | 1 | |a De Silva, Thilinie |e investigator |4 oth | |
| 700 | 1 | |a Hall, Stephen |e investigator |4 oth | |
| 700 | 1 | |a Mckay, Nicole |e investigator |4 oth | |
| 700 | 1 | |a Murdoch, Louise |e investigator |4 oth | |
| 700 | 1 | |a Ostor, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Smith, Deon |e investigator |4 oth | |
| 700 | 1 | |a Burnet, Simon |e investigator |4 oth | |
| 700 | 1 | |a New-Tolley, Julia |e investigator |4 oth | |
| 700 | 1 | |a Quinlivan, Alannah |e investigator |4 oth | |
| 700 | 1 | |a Rischmueller, Maureen |e investigator |4 oth | |
| 700 | 1 | |a Tieu, Joanna |e investigator |4 oth | |
| 700 | 1 | |a Blockmans, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Vanderschueren, Steven |e investigator |4 oth | |
| 700 | 1 | |a Henckaerts, Liesbet |e investigator |4 oth | |
| 700 | 1 | |a De Munter, Paul |e investigator |4 oth | |
| 700 | 1 | |a Carron, Philippe |e investigator |4 oth | |
| 700 | 1 | |a Peene, Isabelle |e investigator |4 oth | |
| 700 | 1 | |a Piette, Yves |e investigator |4 oth | |
| 700 | 1 | |a Van Den Bosch, Filip |e investigator |4 oth | |
| 700 | 1 | |a Bergeron, Claudie |e investigator |4 oth | |
| 700 | 1 | |a Dupont, Annie |e investigator |4 oth | |
| 700 | 1 | |a Fortin, Isabelle |e investigator |4 oth | |
| 700 | 1 | |a Keyaert, Delphine |e investigator |4 oth | |
| 700 | 1 | |a Muhoza Butoke, Christian |e investigator |4 oth | |
| 700 | 1 | |a Drouin, Julie |e investigator |4 oth | |
| 700 | 1 | |a Lessard, Clode |e investigator |4 oth | |
| 700 | 1 | |a Morin, Frederic |e investigator |4 oth | |
| 700 | 1 | |a Nguyen, Patrick |e investigator |4 oth | |
| 700 | 1 | |a Payette, Marie-Pier |e investigator |4 oth | |
| 700 | 1 | |a Tremblay, Jean-Luc |e investigator |4 oth | |
| 700 | 1 | |a Allard-Chamard, Hugues |e investigator |4 oth | |
| 700 | 1 | |a Arsenault, Guylaine |e investigator |4 oth | |
| 700 | 1 | |a Boire, Gilles |e investigator |4 oth | |
| 700 | 1 | |a Liang, Patrick |e investigator |4 oth | |
| 700 | 1 | |a Masetto, Ariel |e investigator |4 oth | |
| 700 | 1 | |a Garner, Stephanie |e investigator |4 oth | |
| 700 | 1 | |a Khalidi, Nader |e investigator |4 oth | |
| 700 | 1 | |a Kiseleva, Natalia |e investigator |4 oth | |
| 700 | 1 | |a Ojassalu, Ene |e investigator |4 oth | |
| 700 | 1 | |a Raussi, Eve-Kai |e investigator |4 oth | |
| 700 | 1 | |a Tuvik, Piia |e investigator |4 oth | |
| 700 | 1 | |a Khoury, Gisele |e investigator |4 oth | |
| 700 | 1 | |a Legouffe, Marie-Christine |e investigator |4 oth | |
| 700 | 1 | |a Morel, Jacques |e investigator |4 oth | |
| 700 | 1 | |a Mouterde, Gael |e investigator |4 oth | |
| 700 | 1 | |a Assaraf, Morgane |e investigator |4 oth | |
| 700 | 1 | |a Leroux, Gaelle |e investigator |4 oth | |
| 700 | 1 | |a Banneville, Béatrice |e investigator |4 oth | |
| 700 | 1 | |a Boleto, Gonçalo |e investigator |4 oth | |
| 700 | 1 | |a Ferfar, Yasmina |e investigator |4 oth | |
| 700 | 1 | |a Saadoun, David |e investigator |4 oth | |
| 700 | 1 | |a Vautier, Mathieu |e investigator |4 oth | |
| 700 | 1 | |a Carvajal Alegria, Guillermo |e investigator |4 oth | |
| 700 | 1 | |a Cornec, Divi |e investigator |4 oth | |
| 700 | 1 | |a Kervarrec, Patrice |e investigator |4 oth | |
| 700 | 1 | |a Guellec, Dewi |e investigator |4 oth | |
| 700 | 1 | |a Devauchelle, Valérie |e investigator |4 oth | |
| 700 | 1 | |a Houssais, Camille |e investigator |4 oth | |
| 700 | 1 | |a Jousse-Joulin, Sandrine |e investigator |4 oth | |
| 700 | 1 | |a Marhadour, Thierry |e investigator |4 oth | |
| 700 | 1 | |a Saraux, Alain |e investigator |4 oth | |
| 700 | 1 | |a Cassim, Veronique |e investigator |4 oth | |
| 700 | 1 | |a Eloy, Capucine |e investigator |4 oth | |
| 700 | 1 | |a Flipo, Rene-Marc |e investigator |4 oth | |
| 700 | 1 | |a Philippe, Peggy |e investigator |4 oth | |
| 700 | 1 | |a Boyer Jean, Frédéric |e investigator |4 oth | |
| 700 | 1 | |a Cantagrel, Alain |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 389(2023), 14 vom: 05. Okt., Seite 1263-1272 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:389 |g year:2023 |g number:14 |g day:05 |g month:10 |g pages:1263-1272 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMoa2303452 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 389 |j 2023 |e 14 |b 05 |c 10 |h 1263-1272 | ||